View in EDS

Real-world clinical outcomes and economic burden of discontinuation of taxane therapy among patients with metastatic castration-resistant prostate cancer.

Saved in:
Bibliographic Details
Title: Real-world clinical outcomes and economic burden of discontinuation of taxane therapy among patients with metastatic castration-resistant prostate cancer.
Authors: Shore, Neal1 (AUTHOR) nshore@auclinics.com, Nguyen2 (AUTHOR), Kang, Barinder2 (AUTHOR), Sawhney, Amrita2 (AUTHOR), Byrne, Clare3 (AUTHOR), Tang, Jackson3 (AUTHOR), Gorritz, Magdaliz4 (AUTHOR), Chen, Chi-Chang4 (AUTHOR), Patel, Jeetvan2 (AUTHOR)
Source: International Journal of Clinical Oncology. Aug2026, Vol. 31 Issue 8, p1451-1471. 21p.
Database: Academic Search Ultimate
Description
ISSN:13419625
DOI:10.1007/s10147-026-03102-2